Anixa Biosciences (ANIX) Asset Utilization Ratio (2011 - 2023)

Anixa Biosciences' (ANIX) quarterly Asset Utilization Ratio came in at 0.01 in Q4 2023, up 3.99% on a QoQ basis from 0.01 in Q3 2023.

Anixa Biosciences (ANIX) Asset Utilization Ratio (2011 - 2023) Analysis & Trends

Anixa Biosciences (ANIX) has 10 years of Asset Utilization Ratio data on file, last reported at 0.01 in Q4 2023.

Quarterly Asset Utilization Ratio changed N/A year-over-year to 0.01 in Q4 2023, while the trailing twelve-month figure through Oct 2023 was 0.01 (changed N/A YoY) and the FY2023 annual result came in at 0.01, changed N/A from the prior year.
Asset Utilization Ratio climbed to 0.01 in Q4 2023, from 0.01 in the prior quarter.
In the past five years, Asset Utilization Ratio ranged from a high of 0.19 in Q2 2019 to a low of 0.01 in Q2 2023.
A 3-year average of 0.04 and a median of 0.02 in 2021 frame the typical range for Asset Utilization Ratio.
The widest YoY moves for Asset Utilization Ratio: up 8.3% in 2019, down 76.49% in 2019.
Tracing ANIX's Asset Utilization Ratio over 3 years: stood at 0.04 in 2019, then sank by 63.31% to 0.01 in 2021, then plunged by 42.55% to 0.01 in 2023.
The last three Asset Utilization Ratio figures came in at 0.01 (Q4 2023), 0.01 (Q3 2023), and 0.01 (Q2 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Vertex Pharmaceuticals	138.83 Bn	130.98 Bn	2.84 Bn	0.47
2	Regeneron Pharmaceuticals	85.79 Bn	77.79 Bn	3.93 Bn	0.38
3	Argenx Se	64.95 Bn	59.77 Bn	1.37 Bn	-
4	Moderna	58.59 Bn	53.46 Bn	52.00 Mn	0.20
5	BeOne Medicines	41.93 Bn	36.83 Bn	1.53 Bn	0.69
6	Alnylam Pharmaceuticals	31.52 Bn	28.21 Bn	992.69 Mn	0.90
7	BioNTech SE	27.98 Bn	9.58 Bn	668.28 Mn	0.13
8	Insmed	27.42 Bn	26.26 Bn	358.27 Mn	0.54
9	Royalty Pharma	27.33 Bn	26.49 Bn	-	0.13
10	Anixa Biosciences	125.30 Mn	125.30 Mn	-	-

Download Data